Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $22.0 million.

  • Neurogene's Cash from Investing Activities rose 17591.66% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.2 million, marking a year-over-year decrease of 381180.53%. This contributed to the annual value of -$125.3 million for FY2024, which is 58859.46% down from last year.
  • Per Neurogene's latest filing, its Cash from Investing Activities stood at $22.0 million for Q3 2025, which was up 17591.66% from $7.4 million recorded in Q2 2025.
  • Neurogene's Cash from Investing Activities' 5-year high stood at $29.9 million during Q1 2024, with a 5-year trough of -$102.6 million in Q4 2024.
  • Over the past 3 years, Neurogene's median Cash from Investing Activities value was -$82000.0 (recorded in 2023), while the average stood at -$10.5 million.
  • Data for Neurogene's Cash from Investing Activities shows a peak YoY increase of 10332413.79% (in 2024) and a maximum YoY decrease of 3522439.02% (in 2024) over the last 5 years.
  • Neurogene's Cash from Investing Activities (Quarter) stood at $25.8 million in 2023, then tumbled by 497.27% to -$102.6 million in 2024, then soared by 121.43% to $22.0 million in 2025.
  • Its Cash from Investing Activities was $22.0 million in Q3 2025, compared to $7.4 million in Q2 2025 and -$45.0 million in Q1 2025.